Genome-wide pharmacogenomic study of citalopram-induced side effects in STAR*D
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Affecting about 1 in 12 Americans annually, depression is a leading cause of the global disease burden. While a range of effective antidepressants are now available, failure and relapse rates remain substantial, with intolerable side effect burden the most commonly cited reason for discontinuation. Thus, understanding individual differences in susceptibility to antidepressant therapy side effects will be essential to optimize depression treatment. Here we perform genome-wide association studies (GWAS) to identify genetic variation influencing susceptibility to citalopram-induced side effects. The analysis sample consisted of 1762 depression patients, successfully genotyped for 421K single-nucleotide polymorphisms (SNPs), from the Sequenced Treatment Alternatives to Relieve Depression (STAR(*)D) study. Outcomes included five indicators of citalopram side effects: general side effect burden, overall tolerability, sexual side effects, dizziness and vision/hearing side effects. Two SNPs met our genome-wide significance criterion (q<0.1), ensuring that, on average, only 10% of significant findings are false discoveries. In total, 12 additional SNPs demonstrated suggestive associations (q<0.5). The top finding was rs17135437, an intronic SNP within EMID2, mediating the effects of citalopram on vision/hearing side effects (P=3.27 × 10(-8), q=0.026). The second genome-wide significant finding, representing a haplotype spanning ∼30 kb and eight genotyped SNPs in a gene desert on chromosome 13, was associated with general side effect burden (P=3.22 × 10(-7), q=0.096). Suggestive findings were also found for SNPs at LAMA1, AOX2P, EGFLAM, FHIT and RTP2. Although our findings require replication and functional validation, this study demonstrates the potential of GWAS to discover genes and pathways that potentially mediate adverse effects of antidepressant medications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
LocusZoom: regional visualization of genome-wide association scan results
Pruim, R. J., Welch, R. P., Sanna, S., Teslovich, T. M., Chines, P. S., Gliedt, T. P., Boehnke, M., Abecasis, G. R., & Willer, C. J. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq419 · Cited by 2,707
Selective publication of antidepressant trials and its influence on apparent efficacy
Turner, E. H., Matthews, A. M., Linardatos, E., Tell, R. A., & Rosenthal, R. (2008) · New England Journal of Medicine · doi:10.1056/nejmsa065779 · Cited by 2,435 · cited 1×
“attain adequate response to their initial antidepressant therapy.(5,6) Compounding the difficulty of identifying successful treatment, antidepressant use is frequently associated with adverse drug reactions, with the inability to tolerate side”
BackgroundReplication of Genome-Wide Association Signals in UK Samples Reveals Risk Loci for Type 2 Diabetes
Zeggini, E., Weedon, M. N., Lindgren, C. M., Frayling, T. M., Elliott, K. S., Lango, H., Timpson, N. J., Perry, J. R. B., Rayner, N. W., Freathy, R. M., et al. (2007) · Science · doi:10.1126/science.1142364 · Cited by 2,194 · cited 1×
“While the lack of involvement in proteincoding sequence somewhat diminishes this marker’s prior probability of being a true discovery, there is precedent for such intergenic associations to replicate in independent samples, such as found with a region on chromosome 9 in Type 2 diabetes mellitus.(78) Furthermore, the a…”
BackgroundSearle, S. R., Casella, G., & McCulloch, C. E. (1992) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316856 · Cited by 1,926
New approaches to antidepressant drug discovery: beyond monoamines
Berton, O., & Nestler, E. J. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1846 · Cited by 1,589
Cohen, J. (1983) · Applied Psychological Measurement · doi:10.1177/014662168300700301 · Cited by 1,564 · cited 1×
“This required data reduction, as using individual PRISE items as GWAS outcomes would provide minimal statistical power, given the presence of substantial measurement error in self-report measures combined with the inherently weak statistical power of dichotomous outcomes.(30,33) Given the limitations of using individu…”
MethodGenetic Mapping in Human Disease
Altshuler, D., Daly, M. J., & Lander, E. S. (2008) · Science · doi:10.1126/science.1156409 · Cited by 1,452
Loehlin, J. C., & Beaujean, A. A. (2016) · doi:10.4324/9781315643199 · Cited by 1,381
Sequenced treatment alternatives to relieve depression (STAR*D): Rationale and design
Rush, A. J., Fava, M., Wisniewski, S. R., Lavori, P. W., Trivedi, M. H., Sackeim, H. A., Thase, M. E., Nierenberg, A. A., Quitkin, F. M., Kashner, T. M., et al. (2004) · Controlled Clinical Trials · doi:10.1016/s0197-2456(03)00112-0 · Cited by 1,076 · cited 4×
“Subjects came from the STAR*D study, which has been described in detail elsewhere.(28) In short, STAR*D is a multistage trial of different treatment options for patients with nonpsychotic MDD.”
MethodInfluential
Cited by
Read, J., & Williams, J. (2018) · Current Drug Safety · doi:10.2174/1574886313666180605095130 · Cited by 175
“Both the ‘Antidepressant SideEffect Checklist’ [10] and the ‘Patient-Rated Inventory of Side Effects (PRISE)’ [11] focus almost exclusively on these bio-medical phenomena and fail to address the psychological or interpersonal domains (although some, such as sexual impairment, can be seen as both biological and interpe…”
BackgroundRead, J., Cartwright, C., & Gibson, K. (2014) · Psychiatry Research · doi:10.1016/j.psychres.2014.01.042 · Cited by 150
Impact of antidepressants on cytokine production of depressed patients in Vitro
Munzer, A., Sack, U., Mergl, R., Schönherr, J., Petersein, C., Bartsch, S., Kirkby, K., Bauer, K., & Himmerich, H. (2013) · Toxins · doi:10.3390/toxins5112227 · Cited by 114
Alexander, J., Potamianou, H., Xing, J., Deng, L., Karagiannidis, I., Tsetsos, F., Drineas, P., Tarnok, Z., Rizzo, R., Wolanczyk, T., et al. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00428 · Cited by 27
The Positive and Negative Experiences of 342 Antidepressant Users
Read, J., Grigoriu, M., Gee, A., Diggle, J., & Butler, H. (2020) · Community Mental Health Journal · doi:10.1007/s10597-019-00535-0 · Cited by 14
Metadata
- Authors
- Adkins, D. E., Clark, S. L., Åberg, K., Hettema, J. M., Bukszár, J., McClay, J. L., Souza, R. P., & van den Oord, E. J. C. G.
- Venue
- Translational Psychiatry
- Published
- 2012-07-03
- Volume
- 2
- Issue
- 7
- Pages
- e129-e129
- ISSN
- 2158-3188 (ISSN-L)
- OpenAlex
- W2008033091
- Cited by
- 52
- References
- 22
- FWCI
- 2.66
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Genome-wide pharmacogenomic study of citalopram-induced side effects in STAR*D. https://app.cochat.ai/papers/10.1038/tp.2012.57
- The paper
- Adkins, D. E., Clark, S. L., Åberg, K., Hettema, J. M., Bukszár, J., McClay, J. L., Souza, R. P., & van den Oord, E. J. C. G. (2012). Genome-wide pharmacogenomic study of citalopram-induced side effects in STAR*D. Translational Psychiatry. https://doi.org/10.1038/tp.2012.57
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.